Anticancer activities and mechanisms of blumea balsamifera extract in hepatocellular carcinoma cells

American Journal of Chinese Medicine

Volumn 36, Issue 2, 2008, Pages 411-424

  Norikura, Toshio ^a   Kojima Yuasa, Akiko ^a   Shimizu, Miki ^a   Huang, Xuedan ^a   Xu, Shenghui ^a   Kametani, Saeda ^a   Rho, Sook Nyung ^b   Kennedy, David Opare ^a   Matsui Yuasa, Isao ^a  

^a Osaka City University   (Japan)

^b Chung Ang University   (South Korea)

Author keywords

A Proliferation Inducing Ligand (APRIL); Blumea balsamifera; Cell Cycle; Cyclin E; Retinoblastoma Protein (Rb)

Indexed keywords

APRIL PROTEIN; BLUMEA BALSAMIFERA EXTRACT; CYCLIN E; PLANT EXTRACT; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLUMEA BALSAMIFERA; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; NONHUMAN; PLANT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ASTERACEAE; CARCINOMA, HEPATOCELLULAR; CYCLIN E; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; G1 PHASE; HUMANS; LIVER NEOPLASMS; PHOSPHORYLATION; PLANT EXTRACTS; RATS; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 44049096609     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X08005862     Document Type: Article

References (28)

1. Anagnostopoulou, M.A., P. Kefalas, V.P. Papageorgiou, A.N. Assimopoulou and D. Boskou. Radical scavenging activity of various extracts and fractions of sweet orange peel (Citrus sinensis). Food Chem. 94: 19-25, 2006.
2. Arimura, T., A. Kojima-Yuasa, M. Suzuki, D.O. Kennedy and I. Matsui-Yuasa. Caspase-independent apoptosis induced by evening primrose extract in Ehrlich ascites tumor cells. Cancer Lett. 201: 9-16, 2003.
3. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
4. Dillon, S.R., J.A. Gross, S.M. Ansell and A.J. Novak. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov. 5: 235-246, 2006.
5. Hahne, M., T. Kataoka, M. Schroter, K. Hofmann, M. Irmler, J.L. Bodmer, P. Schneider, T. Bornand, N. Holler, L.E. French, B. Sordat, D. Rimoldi and J. Tschopp. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med. 188: 1185-1190, 1998.
6. Hanahan, D. and R.A. Weinberg. The hallmarks of cancer. Cell 100: 57-70, 2000.
7. Hasegawa, H., Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Yoshida, T. Sakai, T. Koyano, T.S. Kam, K. Murata, K. Sugahara, K. Tsuruda, N. Akamatsu, K. Tsukasaki, M. Masuda, N. Takasu and S. Kamihira. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood 107: 679-688, 2006.
8. Helin, K. Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev. 8: 28-35, 1998.
9. Huang, X., A. Kojima-Yuasa, T. Norikura, D.O. Kennedy, T. Hasuma and I. Matsui-Yuasa. Mechanism of the anti-cancer activity of Zizyphus jujuba in HepG2 cells. Am. J. Chin. Med. 35: 517-532, 2007.
10. Kato, J., H. Matsushime, S.W. Hiebert, M.E. Ewen and C.J. Sherr. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7: 331-342, 1993.
11. Kennedy, D.O., A. Kojima, J. Moffatt, H. Yamagiwa, Y. Yano, T. Hasuma, S. Otani and I. Matsui-Yuasa. Cellular thiol status-dependent inhibition of tumor cell growth via modulation of retinoblastoma protein phosphorylation by (-)-epigallocatechin. Cancer Lett. 179: 25-32, 2002.
12. Llovet, J.M., J. Bustamante, A. Castells, R. Vilana, C. Ayuso Mdel, M. Sala, C. Bru, J. Rodes and J. Bruix. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 29: 62-67, 1999.
13. Lopez-Fraga, M., R. Fernandez, J.P. Albar and M. Hahne. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2: 945-951, 2001.
14. Matsumoto, Y., K. Hayashi and E. Nishida. Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr. Biol. 9: 429-432, 1999.
15. Moldeus, P., J. Hogberg and S. Orrenius. Isolation and use of liver cells. Methods Enzymol. 52: 60-71, 1978.
16. Newman, D.J., G.M. Cragg and K.M. Snader. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66: 1022-1037, 2003.
17. Okano, H., K. Shiraki, Y. Yamanaka, H. Inoue, T. Kawakita, Y. Saitou, Y. Yamaguchi, N. Enokimura, K. Ito, N. Yamamoto, K. Sugimoto, K. Murata and T. Nakano. Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization. World J. Gastroenterol. 11: 4650-4654, 2005.
18. Okuda, M., H.F. Horn, P. Tarapore, Y. Tokuyama, A.G. Smulian, P.K. Chan, E.S. Knudsen, I.A. Hofmann, J.D. Snyder, K.E. Bove and K. Fukasawa. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103: 127-140, 2000.
19. Osaki, N., T. Koyano, T. Kowithayakorn, M. Hayashi, K. Komiyama and M. Ishibashi. Sesquiterpenoids and plasmin-inhibitory flavonoids from Blumea balsamifera. J. Nat. Prod. 68: 447-449, 2005.
20. Ragasa, C.Y., A.L. Co and J.A. Rideout. Antifungal metabolites from Blumea balsamifera. Nat. Prod. Res. 19: 231-237, 2005.
21. Roberts, L.R. and G.J. Gores. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin. Liver Dis. 25: 212-225, 2005.
22. Semenov, I., C. Akyuz, V. Roginskaya, D. Chauhan and S.J. Corey. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk. Res. 26: 271-280, 2002.
23. Senderowicz, A.M. The cell cycle as a target for cancer therapy: Basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 7(Suppl. 3): 12-19, 2002.
24. Stadler, W.M., N.J. Vogelzang, R. Amato, J. Sosman, D. Taber, D. Liebowitz and E.E. Vokes. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J. Clin. Oncol. 18: 371-375, 2000.
25. Stein, J.V., M. Lopez-Fraga, F.A. Elustondo, C.E. Carvalho-Pinto, D. Rodriguez, R. Gomez-Caro, J. De Jong, A.C. Martinez, J.P. Medema and M. Hahne. APRIL modulates B and T cell immunity. J. Clin. Invest. 109: 1587-1598, 2002.
26. Ware, C.F. APRIL and BAFF connect autoimmunity and cancer. J. Exp. Med. 192: F35-38, 2000.
27. Xu, S.B., W.F. Chen, H.Q. Liang, Y.C. Lin, Y.J. Deng and K.H. Long. Protective action of blumeatin against experimental liver injuries. Zhongguo Yao Li Xue Bao 14: 376-378, 1993.
28. Zhang, S.Z., M.M. Lipsky, B.F. Trump and I.C. Hsu. Neutral red (NR) assay for cell viability and xenobiotic-induced cytotoxicity in primary cultures of human and rat hepatocytes. Cell Biol. Toxicol. 6: 219-234, 1990.